- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02250859
A Pharmacokinetic Study of Minocycline in Male and Female Volunteers
An Open-label, Multiple Dose Study to Assess the Pharmacokinetic Profile of Minocycline From FMX-101 Foam (4%) in Male and Female Volunteers
Study Overview
Detailed Description
This is an open-label, single-center, non-randomized, multiple-administrations study in males and females, some of which are with acne.
Twelve (12) subjects will be enrolled to receive a daily dose of topical FMX-101 minocycline (4%) foam for sixteen consecutive days.
Each subject will undergo screening procedures within 21 days prior to dosing, to assess his eligibility to participate in the study, including a dermatological assessment of the acne severity and distribution (for subjects with acne).
On Days 1, 2, 3, 7, 9, 11, 14, 16 and 17 blood will be drawn for PK An End-of Study/Safety Follow-up visit will take place on 7-10 days after last dose, which will also include a dermatological assessment of response to treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tel-Aviv, Israel
- Sourasky Medical Center, Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between 18 and 35 years (inclusive) of age.
- Clear skin or facial acne of any severity, currently untreated
- Otherwise healthy subjects
- Subjects who provide written informed consent to participate in the study.
- Women of childbearing potential who are willing to use 2 reliable methods of contraception or practice abstinence during the study period or be surgically sterilized and agree to undergo repeated pregnancy tests.
- Body Mass Index (BMI) 19.0 to <30.0 kg/m2 and weight ranging between 60-90 kg (males) and 50-85 (females).
- Non-smoking and no use of any tobacco or nicotine products (by declaration) for a period of at least 6 months prior to screening visit
- Subjects in general good health in the opinion of the investigator as determined by medical history, vital signs, ECG and a physical examination.
- Shaven facial hair (males)
- Negative HIV, Hepatitis B and Hepatitis C serology tests at screening.
- No clinically significant abnormalities in hematology, blood chemistry, or urinalysis lab tests at screening.
- No known history of alcohol or drug abuse. Negative urinary screen for drugs of abuse determined within 21 days of the start of the study (screening visit).
- Willingness to minimize exposure to sun for 20 days after first dosing
- Subjects must be able to understand the requirements of the study and must be willing to comply with the requirements of the study
Exclusion Criteria:
- Documented history or ongoing symptoms of significant neurological, renal, cardiovascular, respiratory (asthma), endocrinological, gastrointestinal, hematopoietic disease, neoplasm or any other clinically significant medical disorder, which in the investigator's judgment contraindicate administration of the study medications.
- Known or suspected pregnancy or lactation or planned pregnancy during the study duration (females)
- Use of topical antibiotics or topical corticosteroids for acne treatment within the past 2 weeks.
- Use of systemic corticosteroids within the past 4 weeks.
- Use of systemic retinoids (e.g. isotretinoin) within the past 6 months.
- Concurrent use of medications known to be photosensitizers because of the possibility of augmented photosensitivity.
- History or evidence of skin conditions other than acne (eg, eczema) that would interfere with the subject's participation in the study.
- Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal or dietary supplements within 14 days prior to dosing. Paracetamol or ibuprofen for symptomatic relief of pain is allowed until 24 hours prior to the study drug administration.
- Dermatological conditions which might have an effect upon dermal application, e.g.: Psoriasis, mycosis fungoides, widespread acne, facial or back dermatophytosis, severe hyperhydrosis, chronic or recurrent skin infections, ichtyosis
- Excessive hair in the intended application areas
- Current or recent (within 1year) drug or alcohol abuse.
- Known contraindication, hypersensitivity and/or allergy to the study drug or its excipients.
- Subjects with significant allergic response to other drugs
- Any acute illness (e.g. acute infection) within 48 hours prior to the first study drug administration, which is considered of significance by the Principal Investigator.
- Participation in another clinical trial with drugs received within 3 months prior to dosing (calculated from the previous study's last dosing date).
- Subjects who donated blood in the three months or received blood or plasma derivatives in the six months preceding study drug administration.
- Subjects unable to communicate well with the investigators and CRC staff (i.e., language problem, poor mental development or impaired cerebral function).
- Subjects who are non-cooperative or unwilling to sign consent form.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FMX101 Minocycline 4% foam
FMX101, 4% applied to the face, upper chest, upper back and shoulders for sixsteen consecutive days in subjects either with acne or with normal skin
|
FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events
Time Frame: 22-25 days
|
AEs will be assessed starting from informed consent signature until end of study)
|
22-25 days
|
irritation and local reaction
Time Frame: 16 days
|
The application area will be examined for irritation and local reaction
|
16 days
|
Change from baseline in vital signs
Time Frame: 22-25 days
|
sitting BP, HR, RR, oral temperature
|
22-25 days
|
Cmax
Time Frame: 16 days
|
will be assessed after 1 and 16 days of dosing
|
16 days
|
Tmax
Time Frame: 16 days
|
will be assessed after 1 and 16 days of dosing
|
16 days
|
AUCT
Time Frame: 16 days
|
will be assessed after 1 and 16 days of dosing
|
16 days
|
T½
Time Frame: 16 days
|
will be assessed after 1 and 16 days of dosing
|
16 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jacob Atsmon, MD, Sourasky Medical center, Tel-aviv, Israel
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMX101-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne
-
ProgenaBiomeRecruitingAcne Vulgaris | Acne | Acne Rosacea | Acne Inversa | Acne Keloidalis | Acne Keloid | Acne Conglobata | Acne Cystic | Acne Pomade | Acne Indurata | Acne Papular | Acne Tropica | Acne Urticata | Acne Fulminans | Acne Follicular | Acne Tropicalis | Acne Detergicans | Acne Iodide | Acne VarioliformisUnited States
-
Technische Universität DresdenUnknown
-
Chulalongkorn UniversityCompletedPost - Adolescence AcneThailand
-
National Yang Ming UniversityTaipei City HospitalUnknown
-
Elorac, Inc.Completed
-
Novartis PharmaceuticalsCompletedInflammatory AcneGermany, United States, Hungary, France, Czechia, Netherlands
-
Ulthera, IncCompleted
-
DarierUnknown
-
Seoul National University HospitalCompletedAcne, Photodynamic TherapyKorea, Republic of
-
Cipher Pharmaceuticals Inc.CompletedSevere Nodular AcneUnited States, Canada
Clinical Trials on FMX101, Minocycline 4% foam
-
Vyne Therapeutics Inc.Completed
-
Vyne Therapeutics Inc.CompletedAcne VulgarisUnited States, Dominican Republic
-
Vyne Therapeutics Inc.CompletedAcne VulgarisUnited States, Dominican Republic
-
Vyne Therapeutics Inc.CompletedRosacea | Papulopustular RosaceaGermany
-
Vyne Therapeutics Inc.Premier Research Group plcCompletedFacial Papulopustular RosaceaUnited States
-
Cutia Therapeutics (Shanghai) Co., LtdCompleted
-
Vyne Therapeutics Inc.Premier Research Group plcCompletedFacial Papulopustular RosaceaUnited States
-
Edward Lain, MDVyne Therapeutics Inc.CompletedAcne VulgarisUnited States
-
Vyne Therapeutics Inc.Completed